A Comprehensive Literature Review
Prepared: 2026-09-21 Style: Vancouver numbered citations (all PMIDs mechanically verified via NCBI E-utilities esummary on the date of preparation; registry entries verified via ClinicalTrials.gov v2 API and official registry pages) Note: This review is prepared for personal knowledge; all factual claims carry citation numbers resolved in the reference list.
Abstract
Spontaneous isolated superior mesenteric artery dissection (SISMAD) — dissection confined to the superior mesenteric artery (SMA) without aortic involvement — was long regarded as a rare, frequently fatal event, but its diagnosis has risen sharply with the routinization of computed tomography angiography (CTA) in abdominal imaging [1,2,3,4]. Catalogued demographic and imaging evidence show the typical patient to be a middle-aged man (78–92% male across series) with a mean age of roughly 52–58 years, often a smoker and/or hypertensive, presenting with sudden abdominal pain that is frequently misdiagnosed [5,6,7,8,9]. The first formal clinical practice guideline specifically for SISMAD — the Chinese Spontaneous Isolated Superior Mesenteric Artery Dissection Collaboration Group (ISMAD2022) Guideline, 2025 Edition — was published in Annals of Vascular Surgery in 2026; it issued 19 recommendations across eight topics using GRADE-informed methods and ESC evidence grading, and its own authors emphasized that only a minority of recommendations were supported by high-quality evidence [10]. This review synthesizes the epidemiology, biomechanical pathogenesis (particularly the aortomesenteric angle and SMA curvature), imaging classification systems (Sakamoto, Yun, Li, Luan, Qiu, Tan, and novel hemodynamic-validated schemes), and the full spectrum of management evidence: conservative medical therapy with selective antithrombotics, endovascular stenting and stent-assisted coiling, and open surgical revascularization. Pooled data indicate that upward of 80–90% of symptomatic patients can be safely managed conservatively initially, that antithrombotic agents confer no demonstrable benefit on symptom resolution or remodeling, that roughly 12–31% of patients may eventually require secondary endovascular intervention, depending on definition and population, and that complete false-lumen remodeling is achieved far more frequently after stenting than with medical therapy alone [11,12,13,14,15]. The guideline’s placement within the evolving landscape of mesenteric ischemia guidance (ESVS 2017 and 2025, WSES 2017, ESC/ESVS 2017, SVS 2020, and the 2026 Beijing consensus) is examined, together with open questions, trial-registry status, and the explicit evidence-quality limitations that the guideline itself acknowledges.
1. Introduction and Historical Context
Acute mesenteric ischemia is a group of disorders defined by interruption of blood supply to the intestine; untreated it culminates in intestinal necrosis, and mortality has consistently been reported in the range of 50% despite diagnostic advances [16]. Its estimated incidence is 0.09–0.2% of all acute surgical admissions [16]. Within the spectrum of acute arterial mesenteric ischemia lies a pathologically distinct entity: spontaneous isolated dissection of the superior mesenteric artery, in which an intimal tear and false lumen develop entirely within the SMA, without extension from the aorta and without trauma or an iatrogenic mechanism [17,18,10]. Because the SMA supplies the entire small intestine and proximal colon, severe forms can progress to bowel ischemia, necrosis, arterial rupture, or death, but the modern recognition that most cases follow a benign, self-limited course has fundamentally altered clinical practice [19,17,20].
The history of SISMAD is short and instructive. The first CT-based diagnosis is generally credited to Corbetti and colleagues in 1989, who described two cases in which “lamination of the arterial wall and enhancement of both true and false lumina” were the key CT findings [1]. Three years later, Vignati et al. reported a successful right gastroepiploic artery–to–SMA bypass for an acute ischemic event, noting that only 11 reports of SMA dissection existed in the literature and that most had been fatal [2]. For most of the 1990s, conventional teaching therefore emphasized surgical correction; occasional cases of spontaneous resolution and self-limited clinical courses were described, with Yasuhara et al. in 1998 emphasizing “the role of nonsurgical management with careful follow-up” using duplex and CT [19]. The year 2000 marked the first endovascular treatment of symptomatic SISMAD by percutaneous stent placement (Leung et al.) [21], alongside Sparks et al.’s cautionary report of a patient whose dissection progressed despite anticoagulation and required operative repair — evidence that conservative management could fail [3]. During the same era, small imaging series began to characterize the CT findings (enlarged SMA diameter, intimal flap, thrombosed false lumen or intramural hematoma, and perivascular fat stranding in the mesentery) [22]. By the mid-2000s, Sakamoto et al. had codified a four-type imaging classification and demonstrated that most isolated SMA dissections could be managed conservatively when there were no signs of rupture or bowel ischemia [17]. The following decade produced a wave of series from Korea, China, and Japan — Min 2011, Cho 2011, Park 2011, Luan 2013, Tomita 2016, Kimura 2017, Heo 2017, Kim 2018, and many others — that established conservative-first therapy as the default paradigm for uncomplicated SISMAD and refined the indications for endovascular and surgical rescue [23,24,25,26,27,28,20,29]. Whether the entity itself is truly increasing or is simply being diagnosed far more often because of ubiquitous emergency CTA is a recurring question; the Chinese-language literature alone yielded 622 isolated SMA dissection patients by 2014, a number that would have been unthinkable in the 1990s [4].
The clinical rationale for a dedicated guideline is straightforward: SISMAD is not rare enough to ignore (the Japanese Diagnosis Procedure Combination database identified 715 ISMAD inpatients among 18.3 million admissions between 2010 and 2013) yet is uncommon enough that randomized data are essentially absent [5,6]. Every management question — whether to anticoagulate, whether an asymptomatic dissection needs any intervention, which imaging features mandate stenting, and how aggressively to follow up — has historically been answered by small retrospective series and expert opinion [18,20,10]. The 2025 Chinese guideline is the first to consolidate this evidence into formal recommendations, and its central message — that most recommendations rest on low-quality evidence and that prospective research is urgently needed — is itself a finding of the literature review that follows [10].
This review addresses six questions: (1) What does the 2025 ISMAD2022 guideline recommend and how was it built? (2) What is the epidemiological and imaging-demographic profile of SISMAD? (3) What is known about its biomechanical and genetic pathogenesis? (4) What classification systems exist and which predict outcome? (5) What is the comparative evidence for medical, endovascular, and surgical management? (6) Where does the guideline sit among international mesenteric-ischemia and vascular guidelines, and what are its evidence-quality limits?
2. Epidemiology and Clinical Presentation
2.1 Incidence and Demographic Profile
No true population incidence exists for SISMAD, but several large administrative and registry-based studies provide robust anchoring data. In the Japanese Diagnosis Procedure Combination database covering 18.3 million inpatients (July 2010 to March 2013), Naganuma et al. identified 276 isolated celiac artery dissections (ICAD), 715 ISMAD, 23 isolated splenic, and 11 isolated hepatic artery dissections; males comprised 78–92% and mean age ranged 54.7–56.8 years across groups [5]. A second Japanese administrative study (141 hospitals, 2015) identified 221 ISMAD patients without aneurysm: 90.5% male, mean age 52.5 ± 10.1 years, only one in-hospital death (0.5%), and a mean length of stay of 13.2 ± 9.1 days [6]. A systematic review and meta-analysis pooling 80 reports (1,040 patients with isolated visceral artery dissection) estimated that ISMAD is the most common subtype (pooled prevalence 60%, 95% CI 50–71%), followed by ICAD (37%, 95% CI 27–46%), with an overall male predominance of 80% (95% CI 72–89%) [8]. Similar demographics recur across case series: 90.2% male in Park’s 51-patient series [30]; 92% male among Heo’s 116 patients (mean age 54.7 ± 10.8 years) [20]; 90.9% male in Lei’s 110-patient misdiagnosis study [7]; 86% male in the Hong Kong 78-patient cohort [9]; and 91.4–94% male in recent Chinese treatment series [31,32,33].
2.2 Risk Factors and Comorbidities
The two most consistently identified risk factors are hypertension and smoking. In the ISMAD/ICAD meta-analysis, smoking and hypertension were the top two conditions in both ISMAD (43% and 41%) and ICAD (44% and 32%) patients [8]. In administrative data, hypertension was present in 48–65% of patients with isolated abdominal-branch dissection and 35–65% were smokers [5]. Acosta and Gonçalves’s systematic review of 97 original studies concluded that male sex, hypertension, and smoking are the risk factors for isolated mesenteric artery dissection, while the frequency of diabetes is notably low [34]. Notably, Park et al. compared 51 SISMAD patients to 38 patients with combined aortic and SMA dissection (CASMAD): SISMAD patients were more often male (90.2% vs 71.1%, P = 0.02), less often hypertensive (31.4% vs 65.8%, P = 0.001), and more often carried intra-abdominal cancers (11.8% vs 0%, P = 0.036) — an observation that argues against a purely hypertensive or connective-tissue-driven mechanism and points instead toward local hemodynamic forces at the SMA’s convex curvature [30]. In the Hong Kong cohort (78 patients), 55% had hypertension, and symptomatic SMA-dissection patients were more likely than symptomatic celiac-dissection patients to have thrombosis, significant stenosis, or branch extension [9]. The spectrum of mesenteric vasculopathies also includes segmental arterial mediolysis, fibromuscular dysplasia, localized vasculitis, and wall-thickening without dissection; in a 101-patient single-center analysis, most patients with these overlapping diagnoses improved with conservative management, with only a small minority requiring endovascular or open repair [35]. Underlying heritable arteriopathies are being unmasked by genetic sequencing: in 32 symptomatic ISMAD patients undergoing whole-exome sequencing, 11 (34.4%) harbored pathogenic variants in COL3A1, COL12A1, TLN1, FN1, or TNXB, and COL3A1 variants were strongly correlated with ISMAD and predicted a need for endovascular treatment (P = 0.02) [36]. The complete subclassification of isolated visceral artery dissection — including celiac, superior mesenteric, and renal forms — was examined in a 72-patient series of isolated visceral artery dissection in which conservative management with blood-pressure control, bowel rest, and antiplatelet/anticoagulant drugs achieved symptom resolution and favorable remodeling in most patients, with endovascular bare-metal stenting reserved for persistent pain, lesion progression, marked true-lumen stenosis, or high-rupture-risk false-lumen dilation [37]. Rare causes include iatrogenic and post-transplant mechanisms, most notably isolated SMA dissection in liver transplant recipients (3 of 96 adult recipients in one series), attributed to mechanical stress from retraction of the stomach and SMA root [38].
2.3 Clinical Presentation and the Misdiagnosis Problem
Abdominal pain dominates the clinical picture: 94.5% of patients in the Wenzhou registry presented with abdominal pain [7], 94.6% in a 93-patient endovascular series [31], 91.1% in the Chinese-language literature review [4], and 84.5% in another recent series [32]. Pain is acute in onset, often epigastric or periumbilical, and classically out of proportion to examination. However, the presentation overlaps heavily with common abdominal emergencies, and misdiagnosis is common: among 110 SISMAD patients, 32 (29%) were initially misdiagnosed or missed, with 20 misdiagnosed as SMA embolism; the authors urge considering SISMAD in the differential of unexplained abdominal pain, particularly in men in their fifth decade with hypertension and an enlarged SMA on plain CT [7]. Because symptoms are nonspecific and laboratory tests (C-reactive protein, white cell count, D-dimer) are neither sensitive nor specific, the diagnosis rests on imaging — chiefly CTA [7,16]. Most series report a minority of patients presenting asymptomatically, their dissections discovered incidentally on imaging performed for other indications (e.g., 12 of 51 in Park’s series; 16 of 35 in Kimura’s) [30,28,18]. Symptomatic versus asymptomatic presentation has prognostic relevance: symptomatic patients in Kimura’s series were younger (55.9 ± 13.9 vs 65.3 ± 10.9 years) and more likely to achieve complete remodeling during follow-up [28].
2.4 Natural History
The natural history of conservatively treated SISMAD is largely benign but not trivial. In Park’s landmark natural-history study of 46 conservatively treated patients followed with serial CTA (median 23.0 months), 41.3% showed diminished false-lumen size, 23.9% diminished dissection length, 15.2% complete remodeling, and 43.5% no change; no patient showed dissection progression, and none died of SISMAD, although 26.3% reported nonspecific mild abdominal discomfort [25]. Yun et al. similarly observed no CT progression on follow-up in 28 patients treated conservatively, with or without antithrombotic therapy [39]. Tomita et al. found complete remodeling in 64.0% of 25 symptomatic patients treated conservatively and followed over 2 years, with a patent false lumen and aneurysmal formation on initial CT identified as negative factors for remodeling [27]. Kimura et al. reported complete false-lumen remodeling in 31% overall, associated with the presence of symptoms and the absence of patent false-lumen flow at diagnosis [28]. Heo et al.’s 116-patient series found that among 83 symptomatic patients treated conservatively, 96% achieved pain resolution; 20% later developed recurrent mild abdominal pain (relieved conservatively), and two patients required surgery for bowel stricture; follow-up CTA showed no change in 34%, partial or complete remodeling in 63%, aneurysmal change in 2%, and dissection progression in 1% [20]. Pooled meta-analytic estimates are consistent: complete remodeling after conservative therapy occurs in roughly 25–43% of SISMAD patients at mid-term follow-up, with symptomatic patients remodeling significantly more often than asymptomatic ones (odds ratio 3.95; 95% CI 1.31–11.85 in the Wang 2018 meta-analysis) [40,34]. Long-term all-cause mortality is low: 0–1% in pooled analyses, with dissection-related mortality rarer still [40,6]. The main hazards are progression to bowel ischemia/infarction (peritonitis due to bowel infarction occurs in about 2.1% of SMA dissections and none of celiac dissections [34]; pooled bowel-ischemia rate in conservatively treated patients 3.75%; 95% CI 1.15–7.27 [12]) and, rarely, rupture of a dissecting aneurysm or pseudoaneurysm (approximately 0.4% [34]).
3. Pathogenesis: Biomechanics, Anatomy, and Histology
The mechanism of SISMAD is not atherosclerosis-driven occlusion but a localized arterial-wall failure, and a converging body of clinical-imaging and computational work points to geometric and hemodynamic causes. Park et al. first proposed — based on computational fluid dynamic modeling of the SMA at different branching angles — that abnormal mechanical stresses at the anterior wall of the SMA’s convex portion underlie dissection, and that development of SISMAD is “less likely the result of hypertension or connective tissue disease but more likely due to hemodynamic force caused by convex curvature” [30].
3.1 The Aortomesenteric Angle
The angle between the SMA and the distal aorta (aortomesenteric angle, AMA; or SMA–distal aorta angle) is now the best-replicated anatomical risk factor. Wu et al. compared 37 SISMAD patients with 148 age/gender/BMI-matched controls: SISMAD patients had a larger mean SMA–distal aorta angle (73° ± 19.8° vs 50° ± 18.81°, P < 0.001) and more frequent smoking (62% vs 40%) and hypertension (59% vs 34%); the odds ratio for SISMAD rose with angle category (1, 10, 57, and 73 for <50°, 50–69°, 70–90°, and >90°, P < 0.05 for >70°), and patient-specific fluid–structure interaction modeling showed larger angles associated with higher wall stress and oscillatory shear index at the SMA’s superior convex — precisely where dissections begin [41]. Kim and Labropoulos measured AMA in 45 Korean SISMAD patients versus matched Korean and Caucasian controls: mean AMA was 74.9° in patients versus 62.4° in Korean and 56.8° in Caucasian controls (P < 0.001) [42]. Shi et al. confirmed in 105 patients that each 1° increase in AMA raised SISMAD odds (adjusted OR 1.03) and that intermediate (50–71°) and large (>71°) angles carried adjusted ORs of 2.62 and 4.50 versus <50° [43]. Mechanistically, Jia et al. showed in 122 SISMAD patients with fluid–structure interaction simulation and cadaver histology that aortomesenteric angle (59.7° vs 48.2°) and SMA maximum curvature (0.084 vs 0.032 mm⁻¹) were higher in patients, that these factors concentrate wall shear stress on the anterior wall of the SMA curve, and that this anterior wall is histologically weak: media thickness 325 ± 45 µm (anterior) vs 557 ± 138 µm (posterior), with lower elastin (18.0% vs 27.1%) and collagen (45.4% vs 55.6%) area fractions [44]. A complementary hemodynamic study by the same group demonstrated that vortex formation, high turbulent kinetic energy, and high wall shear stress occur near dissection origins, whereas plaque-driven stenosis occurs at the SMA root — revealing that different portions of the SMA have different wall pathologies and hemodynamic environments [45].
3.2 Curvature, Tortuosity, and 3D Morphology
Beyond the angle, the three-dimensional geometry of the SMA matters. In a two-center case-control study of 60 ISMAD patients, curvature (OR 1.239; 95% CI 1.122–1.369) and tortuosity (OR 0.002; 95% CI 0.000–0.083) were independent morphological predictors of ISMAD — i.e., patients had higher curvature but lower tortuosity than controls [46]. Dou et al.’s CTA-based study of 57 ISMAD patients found that 87% had a right (or near-right) SMA angle and that 90% of entry sites lay in the curved segment of the SMA [47]. French investigators using 3D volumetric and centerline analysis of 17 acute symptomatic IMAD patients matched 1:3 against controls found a +64% larger overall lumen volume and +34% larger overall lumen diameter in patients, no difference in true-lumen volume, a higher 3D aortomesenteric angle at 2 and 4 cm from the ostium, and — among patients with acute mesenteric ischemia — a lower true/overall lumen volume ratio (45% vs 59%) and longer dissections (63 vs 48 mm) [48]. The same group’s prospective volumetric tracking of 15 conservatively treated IMAD patients showed that the true/overall lumen volume ratio rose from 53% at 1 month to 78% at 12 months, with one-third achieving complete remodeling, that smoking and a larger SMA angle at 6 cm from the ostium predicted poorer remodeling, and that these spontaneous remodeling dynamics favor conservative therapy [49]. These morphological findings converge on a single pathological narrative: the SMA originates at a characteristically acute, curved take-off from the aorta, and the anterior wall of this curvature — thin-media, elastin-poor, exposed to high wall shear stress and oscillatory shear at the convexity — is the site of intimal tearing in most cases [30,41,44,47,45].
3.3 Computed Fluid Dynamics of the Dissected Artery
Patient-specific computational fluid dynamics (CFD) has now characterized blood flow within established dissections. Wei and Chen reconstructed a Yun Type I SISMAD: the true lumen showed high-velocity flow concentrated near the entry tear with elevated wall shear stress and time-averaged wall shear stress along the intimal flap, while the false lumen showed low velocity, stasis, low wall shear stress, and oscillatory shear index values exceeding 0.4 (peak 0.45) — a pro-thrombotic environment that explains both false-lumen thrombosis and flap instability [50]. Mei et al. used CFD to show that in type IIa SISMAD, false-lumen changes (degree of collapse on follow-up) correlate positively with false-lumen length and the false-lumen-length/dissection-entrance-length ratio and with high relative-residence-time area, and negatively with time-averaged wall shear stress, vorticity, symptom duration, and other hemodynamic measures [51]. A validation study of the Qiu classification used CFD across 62 ISMAD patients and found significant hemodynamic differences among morphological types (e.g., Type IV showed highest time-averaged wall shear stress; Type II highest oscillatory shear index), supporting the physiological plausibility of morphology-driven classification [52]. These modeling studies are the intellectual bridge between imaging classification and clinical decision-making, and are discussed further in Section 5.
4. Diagnosis and Imaging
4.1 CTA: The Diagnostic Standard
Contrast-enhanced CTA is the diagnostic gold standard for SISMAD and, more broadly, for acute mesenteric ischemia; the WSES guidelines recommend prompt CT angiography to establish the diagnosis [16]. The ACR Appropriateness Criteria likewise identify CTA of the abdomen and pelvis as the most appropriate examination in both acute and chronic mesenteric ischemia [53]. CTA establishes the presence of an intimal flap and false lumen, distinguishes isolated SMA dissection from aortic extension, quantifies true-lumen stenosis, identifies entry/re-entry sites, and screens for visceral or bowel compromise and collateral circulation. In the Chinese-language SISMAD literature, contrast-enhanced CT diagnosed 95.2% of patients [4]. Early CT descriptions emphasized enlargement of the SMA (5 of 6 cases), intimal flap or thrombosis of the false lumen (4 of 6 each), perivascular fat stranding (5 of 6), and — in one case — mesenteric hematoma with hemorrhagic ascites [22]. On plain (unenhanced) CT, perivascular fat stranding around the SMA may be the only pointer to SISMAD, and Tan et al. showed it significantly associates with emergency admission, abdominal pain, contrast-enhanced diagnosis, and dissection subtype, recommending that PFS on plain CT mandate CTA [54]. The SMA–SMV diameter ratio on non-enhanced CT is a newer diagnostic adjunct: in 97 SISMAD patients versus 194 matched abdominal-pain controls, the SMA/SMV ratio had an area under the ROC curve of 0.956 (cutoff 0.83; sensitivity 88.7%, specificity 92.3%), out-performing maximum SMA diameter alone (AUC 0.926) [55]. A maximum SMA diameter of 12.1 (IQR 11.3–13.1) mm on plain CT, maximal at the left-renal-vein plane in 68.2%, is described in the Wenzhou misdiagnosis cohort [7].
4.2 Ultrasound and Other Modalities
Duplex ultrasonography has a secondary diagnostic and surveillance role, and typical abnormal findings were described as early as 2010 [56,19]. However, in emergency practice, operator dependence and bowel gas limit its reliability, and it does not replace CTA for characterization of the false lumen or true-lumen stenosis. Ultrasound remains useful for post-diagnosis trend monitoring in selected patients [56,18]. Conventional arteriography and intravascular ultrasound (IVUS) can be adjuncts during endovascular treatment — IVUS was used to confirm true-lumen guidewire position during acute-phase stenting in one reported case [57] — but are not first-line diagnostic tools. Multi-slice spiral CT angiography with post-processing is a well-characterized technique for isolated visceral artery dissection, with type I/IIa/IIb configurations reliably distinguished and the false lumen larger than the true lumen in most patients [58].
4.3 Imaging Triggers for Intervention
Several imaging features are repeatedly used in the literature to escalate care: severe true-lumen compression (>80% stenosis in Min’s definition, or >70% stenosis in the JVIR conservative-safety series) [23,59]; dissection length ≥50 mm, which Shi et al. identified as an independent risk factor for failed conservative treatment (OR 4.68; 95% CI 1.29–16.98) [60]; symptomatic dissection with a patent false lumen or aneurysmal formation (negative remodeling factors) [27]; progressive false-lumen aneurysm or a large dissecting aneurysm [23]; and signs of bowel ischemia or arterial rupture, which are absolute indications for surgery [34,18]. Dou et al. found that the diameter of the true lumen was the only CTA feature distinguishing the conservative from the interventional treatment groups in their 57-patient series (P = 0.000), while re-entry site, false-lumen thrombosis, entry-to-root distance, and branch involvement did not differ [47]. Chen et al. demonstrated that even patients with a severely compressed true lumen (>70% stenosis) or large dissecting aneurysm could be safely treated with primary conservative therapy when there was no intestinal necrosis or rupture: all 35 patients responded, with abdominal pain eliminated within a mean 4.7 ± 4.8 days and complete or partial remodeling achieved in 17.1% and 82.9% during follow-up — a direct challenge to the automatic-stenting reflex for these ominous-appearing morphologies [59].
5. Classification Systems
Multiple imaging classification systems have been proposed for SISMAD, reflecting its morphological polymorphism and the need to predict which patients will fail conservative management [61,47,10]. The major schemes are summarized in Table 2.
5.1 Sakamoto Classification (2007)
Based on 12 patients, Sakamoto et al. divided isolated SMA dissection into four imaging types: type I, patent false lumen with both entry and re-entry; type II, “cul-de-sac” shaped false lumen without re-entry; type III, thrombosed false lumen with an ulcer-like projection (ULP — a localized blood-filled pouch protruding from the true lumen into the thrombosed false lumen); and type IV, completely thrombosed false lumen without ULP [17]. In their series, one type II patient required urgent surgery for small-bowel ischemia, one type III patient required urgent embolization for a ruptured branch, and the remaining ten were managed conservatively; one type III patient’s ULP progressively dilated and was treated by stenting plus coil packing at 22 months [17]. In a U.S. series of 40 patients with spontaneous isolated celiac or SMA dissection, Sakamoto type IV (completely thrombosed) lesions were more likely to remodel spontaneously (odds ratio 11.26; 95% CI 1.13–588.26, P = 0.039) whereas type II lesions were less likely to remodel, and most patients improved with medical therapy alone [62]. The Sakamoto system underpins management triage in many later series [63,33]. Yoshida et al. found initial Sakamoto types in acute SISMAD were predominantly III and IV, and that these could evolve to type I during observation; three of 13 acute patients required bowel resection [63]. In Huang’s 2025 series of 136 SISMAD patients, Sakamoto types predicted treatment: conservative vs interventional rates were type I 40.7% vs 59.3%, type II 20% vs 80%, type III 52.9% vs 47.1%, and type IV 82.1% vs 17.9% (P = 0.001) — i.e., type IV (completely thrombosed) dissections responded well to conservative care [33].
5.2 Yun Classification
Yun and colleagues’ classification, based on CT configuration, is frequently cited in Korean and Chinese practice, with subtypes such as type I (patent false lumen with both entry and re-entry) and type IIa/IIb used across series [29,54,7,52]. In Kim et al.’s no-antithrombotic series, SISMAD was categorized into four types per Yun’s classification, and improvement or complete resolution with no symptom recurrence was seen in 27 of 29 patients [29]. In the Wenzhou registry, 63.6% of dissections were Yun type IIb [7]. Because the primary-source definitions of the Yun subtypes are not captured in this review’s verified abstract record, the subtypes should be treated as operational definitions used consistently across these clinical studies rather than as independently re-derived here.
5.3 Li and Luan Classifications
Li’s classification (types I–V) is a morphology-based scheme that Jia et al. described as “more precise and complete compared to other classification systems and can be used to guide the treatment of SISMAD” [61]. It is widely used in Chinese practice and was the operative classification in the Riolan’s-arch study [64] and in the 70-patient CFD study underlying the novel HX classification [65]. The Luan classification has also been employed, with conservative outcomes reported best for Luan type B lesions [4]. Complete subtype definitions of Li’s and Luan’s schemes are available in the primary papers but are not itemized in the verified abstracts used here; they are therefore referenced qualitatively.
5.4 Qiu Classification and Hemodynamic Validation
More recently, a systematic five-type scheme (Type I–V by false-lumen structure, plus Type P vs Type S by true-lumen patency) — the “Qiu classification” — was proposed and subjected to formal computational validation: Zhang et al. reconstructed 62 ISMAD patients and showed significant differences in time-averaged wall shear stress, oscillatory shear index, relative residence time, pressure gradients, and volumetric flow across categories, e.g., Type IV higher TAWSS (P = 0.007), Type II higher OSI (P = 0.015), and Type S worse pressure-drop/OSI/RRT than Type P [52]. This represents the clearest attempt yet to ground a morphological classification in flow physics.
5.5 Novel Hemodynamic (HX) Classification
Xu et al. argued that patients with the same Li type can have meaningfully different blood-flow patterns, and proposed the HX classification: Type I (dual-lumen flow type, subdivided Ia/Ib) and Type II (single-lumen flow type), with intervention thresholds derived from follow-up: a rupture-area/entrance-area ratio >0.44 for Type I and a minimum/maximum diameter ratio <0.38 for Type II [65]. This scheme is novel and not yet externally validated.
5.6 Which Classification Predicts Outcome?
The evidence base on predictive performance is now quantitative. Ling et al. (ISMAD2022 collaboration) compared the predictive value of eight imaging classification systems for conservative-management failure in 156 SISMAD patients from three Chinese centers: conservative management failed in 48 (30.8%). Patients who failed had longer pre-admission abdominal pain (median 8 vs 4 days, P = 0.021) and more severe SMA stenosis (0.83 vs 0.64, P = 0.005). Among all eight systems, Tan’s classification showed the best model fit (AIC 186), the highest discrimination (C-statistic 0.750; 95% CI 0.670–0.830), the greatest net reclassification improvement (0.593; 95% CI 0.244–0.903), good calibration, and the highest net benefit in decision-curve analysis [66]. The accompanying editorial, “Beyond Classification,” calls for risk-stratification approaches that move past static morphology to incorporate dynamic, multi-dimensional behavior — a theme echoed in the guideline’s own acknowledgement of weak evidence [67,10]. The implication for the guideline is practical: classification is used to decide who can be observed versus who should be considered for early intervention, but no single system is yet authoritative [61,10,66].
6. Management Evidence
6.1 The Conservative-First Paradigm
Every major series and meta-analysis converges on the finding that most SISMAD patients — symptomatic and asymptomatic — can be treated initially with conservative measures: bowel rest, intravenous fluids, nutritional support, blood-pressure control with antihypertensives, and analgesia [39,24,23,20,29,34,10]. In the 2018 meta-analysis of 25 articles (616 SISMAD cases; 514 symptomatic), initial treatment was conservative in 447 patients (87.0%) and surgical/interventional in 67 (13.0%); conservative treatment had an 84.7% pooled success rate and a 14.3% conversion-to-intervention rate [11]. In Karaolanis’s meta-analysis (30 studies, 729 patients), symptomatic patients were managed conservatively (438/72%), endovascularly (139/22.8%), or with open surgery (31/5%); resolution of symptoms was 92.8% for conservative treatment, 88.8% for endovascular, and 100% for open repair; conversion from conservative to endovascular or open was required in 12.3% and 4.4%, respectively; complete and partial remodeling under conservative care were 32% and 26% [12]. In the ISMAD2016 review of Chinese-language reports, only 63.2% of patients received primary conservative management and symptom relief rates were 62.6% with and 86.5% without anticoagulation — early evidence that antithrombotics might be unnecessary or even unhelpful [4].
Blood-pressure control appears important both acutely (to reduce wall stress on the weakened segment) and long-term, and 66.1% of patients in the Japanese administrative cohort received antihypertensive therapy during hospitalization [6,34,10]. Oral intake is typically withheld initially and reintroduced only after symptom control, with fasting times of roughly 2.5 days (primary stenting) versus 8.0 days (conservative) reported in Min’s comparative analysis [23]. In the U.S. experience of Mount Sinai, 8 of 10 patients with celiac or mesenteric dissection were managed by observation without anticoagulation and the disease stabilized in all patients during follow-up — reinforcing that even symptomatic patients frequently have a self-limited course [68].
6.2 The Antithrombotic Controversy
Whether to use antiplatelet agents or anticoagulants during conservative management is the single most contested question in SISMAD care, and the accumulated evidence now supports a “less is more” position. Observational comparisons found no difference in outcome between anticoagulated/non-anticoagulated patients (Yun: no difference, P = 1.00 [39]) and variable results in Chinese data [4]. Kim et al. treated 29 consecutive SISMAD patients without any antithrombotics and found conservative treatment without antithrombotics sufficient in patients without bowel ischemia or infarction on initial CT [29]. Zhu et al.’s meta-analysis found conservative-treatment failure rates of 17.8% with versus 10.1% without antithrombotic therapy (P = 0.103) — a point estimate favoring no antithrombotics, though not statistically significant [11]. The definitive analysis is the meta-analysis by Ahn et al. (35 articles, 727 patients): there was no significant difference in successful resolution between conservative management with and without antithrombotics (risk ratio 0.96; 95% CI 0.87–1.05), whether analyzed as two-arm comparisons or pooled single-arm series (91% vs 95% resolution; RR 0.97; 95% CI 0.91–1.02), and no difference in morphological progression or adverse events; the authors concluded “we do not recommend the use of antithrombotics for SID-SMA, unless further evidence shows any beneficial effect” [13]. Heo’s natural-course series likewise found no beneficial effect of antithrombotic therapy on either clinical or morphologic outcomes [20]. Acosta’s systematic review concluded there is no support for antithrombotic agents in conservative therapy [34]. On the basis of such data, the 2025 guideline addresses antithrombotics in its medical-management recommendations (Section 7); the direction of the evidence is that routine antithrombotic therapy is not beneficial for the majority [13,34,10].
6.3 Endovascular Treatment
Endovascular therapy — bare self-expanding stents, with or without false-lumen coiling (bare stent-assisted coiling, BMSAC) — is the dominant rescue and primary-intervention modality in symptomatic, complicated, or progressive disease [21,26,23,61,34]. Indications repeatedly cited are: persistent or recurrent symptoms despite conservative management; severe true-lumen compression (>70–80% stenosis); dissecting aneurysm ≥2.0 cm (Min) or ≥1.5× normal caliber; dissecting aneurysm at risk of rupture; bowel ischemia without established infarction; and disease progression on follow-up imaging [23,61,34,59,10]. Technical success rates are high: 86.5% in Gao’s stable-symptomatic cohort [69]; 90.2% in Xu et al.’s 51-patient endovascular series [70]; ~94% technique success and ~99% symptom resolution in the pooled meta-analysis of 611 endovascularly treated patients [71]. Complications are uncommon (~1%), mortality <1%, and reintervention <1% in pooled endovascular data [71]. Stent patency is high (98%) and complete remodeling reaches 88% after stenting in pooled analyses [71].
The comparative evidence is more nuanced. Gao et al. (94 stable symptomatic patients; 37 endovascular after initial medical management vs 57 medical alone) found composite major-adverse-event-free survival was similar (95.6%, 88.9%, 85.4% at 1, 3, and 5 years), but endovascular patients achieved more complete/partial remodeling (81.1% vs 44.4%; P < 0.0001) and greater freedom from SMA stenosis/occlusion (log-rank P = 0.046) [69]. Xu et al. (42 patients; 27 endovascular vs 15 conservative) reported higher remodeling (P < 0.001) and longer symptom-free survival (P = 0.014) in the endovascular group [72]. The ten-year retrospective study by Wang et al. (226 patients; 191 endovascular, 35 medical) reported freedom from adverse events of 91.8% vs 79.6% at 60 months and 87.6% vs 74.6% at 120 months, and complete remodeling rates of 69.3% vs 29.0% at 60 months — differences that persisted after propensity-score matching — favoring endovascular treatment [14]. Conversely, Wang et al.’s 2024 meta-analysis of endograft therapy versus medical treatment (9 observational studies, 672 patients) found no significant differences in early symptom alleviation, reintervention, or all-cause mortality; endovascular patients had a longer reported hospital stay (13.2 ± 5.1 vs 7.0 ± 2.2 in the units stated in the source, evidently days, P < 0.01) but significantly higher long-term complete remodeling (OR 4.53; 95% CI 3.01–6.81) and lower aneurysm formation (OR 0.19; 95% CI 0.06–0.60) [15]. The Zhang 2024 meta-analysis therefore separates the endpoints: stenting greatly improves anatomical remodeling but has not been shown to improve mortality, symptom recurrence, or reintervention needs [15]. In acute comparisons, stenting shortens fasting time and hospital stay versus continued conservative care and rapidly relieves pain (median time to symptom relief 1 day in Ji’s 26-patient bare-stent series) [23,73].
Stent type and configuration matter. Bare self-expanding stents that fully cover the SMA curvature are recommended; several groups report that covering the dissection entry and landing proximally (near or in the abdominal aorta) reduces in-stent restenosis [26,74]. In-stent restenosis is the principal long-term technical liability: pooled stent-stenosis rate was 12% (95% CI 0.04–0.23) [71]; in a case-control study of 26 ISR patients, stent-to-vessel ratio (OR 1.14), stent proximal position >10 mm from the SMA root (OR 108.67), and high oscillatory-shear-index area (OR 1.25) predicted restenosis [74]. Coil-assisted stenting (BMSAC) achieves higher complete remodeling than bare stents alone: 100% vs 46.3% in Qi’s 121-patient comparison (P < 0.0001) [75]; 95.8% vs 73.7% in Huang’s 136-patient series (P = 0.039) [33]; and 100% in the stent-assisted-coiling group of Weng’s 93-patient series versus 84.1% for stenting alone (P < 0.001) [31]. Coiling targets the false lumen to accelerate thrombosis and remodeling; case reports describe false-lumen coiling through a double-catheter/micro-balloon technique [76]. Vasodilator infusion (catheter-directed) has been used as an adjunct after stenting, and in Luan’s 2013 experience a vasodilator was infused directly in four patients as definitive treatment [26]. Patients treated endovascularly are routinely placed on dual antiplatelet therapy or at least aspirin after stenting, though the optimal regimen is not established by trials [23,36].
Approach and access: femoral or brachial puncture; seven-Fr guiding catheters through the lesion; 0.014-inch guidewire through the true lumen, ideally under IVUS or road-map control; balloon pre-dilation of severe stenosis; and deployment of self-expanding stents sized to the normal distal SMA (typically 6–8 mm), with post-dilation as needed [26,57,73,70].
6.4 Open Surgery and Hybrid Approaches
Open surgery is reserved for patients with established or impending bowel infarction, arterial rupture, peritonitis, gangrene, or failure of both conservative and endovascular approaches; it is performed without delay and usually combines bowel resection with revascularization [34,18,10]. Historical revascularization options include thromboendarterectomy plus patch angioplasty, aorto/SMA bypass with autologous vein, and the right-gastroepiploic-artery–to–SMA bypass first described by Vignati [2,3,77]. An original technique — superficial femoral artery transposition to the SMA — was reported by Picquet after failure of conservative management [78]. In symptomatic Chinese series, open repair has the highest (100%) symptom-relief rate though with small numbers [4]; in pooled meta-analytic data, open repair resolved symptoms in 100% but was applied in only ~4.3–5% of patients [12,11]. Bowel infarction requiring resection occurs in roughly 2.1% of SMA dissections [34]. Retrograde open mesenteric stenting (ROMS), a hybrid technique, is reported mainly in atherosclerotic chronic mesenteric ischemia and is a salvage option in the broader mesenteric-ischemia armamentarium rather than a first-line SISMAD procedure [79]. Operative management of SISMAD in specialized centers is exceptional in the modern era, underscoring the paradigm shift from surgery-first to conservative-first care [18,20,10]. It is instructive to contrast outcomes across the visceral-dissection family: in a comparative single-center registry study, symptomatic isolated renal artery dissection managed conservatively was associated with a substantially higher rate of dissection-related mortality (17% vs 0%, P = 0.016) and need for intervention (39% vs 10%, P = 0.009) than concurrent symptomatic isolated SMA dissection — evidence that SISMAD is among the more benign members of this disease family and that aggressive intervention should be weighed carefully [80].
6.5 Treatment Selection: The Decision Architecture
Synthesis of the evidence yields a decision architecture that the guideline formalizes:
- All patients undergo CTA to establish diagnosis, classification, and risk features.
- Asymptomatic patients are treated conservatively (blood-pressure control, observation), with remarkably low secondary-intervention rates: 0% in pooled meta-analysis of asymptomatic patients [40,11].
- Symptomatic patients without risk features are treated conservatively first; blood pressure control, bowel rest, analgesia. Antithrombotics are not recommended routinely [13,34,10].
- Endovascular treatment is offered for persistent/recurrent symptoms, severe true-lumen stenosis, dissecting aneurysm at risk of rupture, dissection progression, or evidence of ischemia — either as primary therapy in clearly high-risk morphology or after failed conservative therapy [23,60,10,66].
- Open surgery is reserved for bowel infarction, peritonitis/necrosis, rupture, or failed endovascular treatment [34,61].
- After any treatment, CTA surveillance is routine (typically at 1–3–6 months then yearly), guided by symptoms; remodeling, true-lumen patency, aneurysm formation, and in-stent restenosis are tracked [20,27,29,74].
The most heavily used quantitative triggers in the literature are a true-lumen stenosis of 70–80% or greater [23,59], a dissecting aneurysm ≥2 cm in diameter [23] or ≥1.5× the normal arterial caliber [59], dissection length ≥50 mm [60], and failure of symptom control after an initial 3-day conservative trial — although even after 3-day failure, continued conservative care remains safe in a 10-year follow-up comparison (clinical complete recovery 31/38 vs 12/19, P = 0.19) with vastly lower cost, while stenting produced radiologic remodeling (16/19 vs 6/38, P < 0.01) [81].
7. The 2025 Chinese (ISMAD2022) Guideline in Detail
7.1 Guideline Development and Methodology
The Clinical Practice Guideline for Spontaneous Isolated Superior Mesenteric Artery Dissection (2025 Edition) was developed by the Chinese Spontaneous Isolated Superior Mesenteric Artery Dissection Collaboration Group (ISMAD2022), under the coordination of Xiangya Hospital, Central South University, in collaboration with major Chinese vascular centers; Wang W (Xiangya) is listed as the corresponding coordinating author [10]. The guideline was published in Annals of Vascular Surgery (2026;132:169–186; Epub 23 June 2026) [10]. Methodologically, it adopted an approach “informed by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology and the European Society of Cardiology grading system,” with recommendation classes by evidence quality categorized as high (level A), moderate (level B), or low (level C) [10]. After reviewing the literature on eight topics — including clinical presentation, imaging evaluation, classification, medical management strategies, and follow-up — the writing committee issued 19 recommendations [10]. Crucially, the guideline’s own conclusion states that among the 19 recommendations, only a minority were supported by high-quality evidence, “underscoring the urgent need for further well-designed clinical studies and prospective research to refine the management of SISMAD” [10]. This self-assessment is the single most important interpretive statement about the guideline: it is an evidence-graded blueprint in a field that currently rests on case series and meta-analyses of case series rather than randomized trials.
7.2 The Eight Topics and 19 Recommendations (Summary of Accessible Record)
The complete itemized text of the 19 recommendations is not available in the published abstract used here (the full text requires subscription); Table 1 accordingly summarizes the guideline’s scope as recorded in the verified abstract and its companion analyses rather than reproducing each numbered recommendation verbatim. The eight covered topics span clinical presentation, imaging evaluation, classification, medical management strategies, and follow-up (plus interventional/surgical and related subtopics consistent with the guideline’s scope statement) [10]. Companion work from the same group — the JACC Asia 2026 classification-prediction study [66] and its accompanying editorial [67] — provides the quantitative substrate on classification risk-stratification that the guideline’s classification recommendations draw on.
7.3 What the Guideline Changes
Given the paucity of prospective data, the practical contribution of the guideline is organizing and grading what exists. Its direct consequences for clinicians are: (1) explicit statements that conservative management is the recommended first-line strategy for uncomplicated SISMAD, with blood-pressure control and selective therapy rather than routine antithrombotics; (2) endorsement of CTA-based diagnosis and classification; (3) a defined place for endovascular stenting in high-risk morphology or failed conservative therapy, with surgery reserved for ischemia/rupture; and (4) structured follow-up with serial CTA [10,66]. The guideline itself, however, is honest that most of these recommendations are level C, and companion commentary calls for risk-stratification tools that go beyond static classification [67].
8. The Guideline Within the Broader Guideline Landscape
8.1 ESVS 2017 Guidelines on Diseases of Mesenteric Arteries and Veins
The ESVS 2017 clinical practice guidelines addressed the whole spectrum of mesenteric arterial and venous disease, including — within the visceral dissections topic — spontaneous isolated dissection of visceral arteries [82]. They established the conservative-first framework that the Chinese guideline refines, and they emphasized CTA-based diagnosis and endovascular rescue [82].
8.2 ESVS 2025 Guidelines (Mesenteric and Renal)
The ESVS 2025 clinical practice guidelines (the successor document) issued 102 recommendations covering chronic arterial mesenteric ischemia, median arcuate ligament syndrome, acute arterial mesenteric ischemia, non-occlusive mesenteric ischemia, venous mesenteric thrombosis, renal artery and vein disease, visceral artery aneurysms, and — explicitly — spontaneous isolated dissection of the visceral arteries [83]. These guidelines provide the most up-to-date European benchmark against which the Chinese SISMAD guideline can be placed, and both documents share the theme that high-quality trial evidence is lacking for the rarer visceral pathologies [83,10].
8.3 WSES 2017 Acute Mesenteric Ischemia Guidelines
The World Society of Emergency Surgery guidelines position acute mesenteric ischemia as a high-mortality emergency requiring prompt CTA and, where needed, damage-control laparotomy [16]. They are the emergency-medicine anchor for SISMAD care, emphasizing that the rare-visceral-dissection subset must be detected within an expeditious work-up of acute abdominal pain [16].
8.4 ESC/ESVS 2017 Peripheral Arterial Disease Guidelines
The 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases (in collaboration with ESVS) include a mesenteric-artery chapter covering atherosclerotic, embolic, and, in the mesenteric context, occlusive and ischemic presentations [84]. They provide the ESC class/level grading framework that the ISMAD2022 guideline partially adopts (ESC class I–III with A/B/C evidence), situating SISMAD recommendations inside a familiar cardiovascular grading language [10,84].
8.5 SVS 2020 Chronic Mesenteric Ischemia Guidelines
The Society for Vascular Surgery’s 2020 chronic mesenteric ischemia practice guidelines focus on atherosclerotic occlusive disease (postprandial pain, food fear, weight loss) and its endovascular-first revascularization [85]. They are relevant as background (chronic ischemia is a distinct entity from acute dissection) and for the principle that long-term surveillance after mesenteric revascularization is mandatory [85].
8.6 The 2026 Beijing Multidisciplinary Consensus on Acute Mesenteric Arterial Ischemia
A 2026 Chinese multidisciplinary expert consensus on acute mesenteric arterial ischemia explicitly excludes isolated SMA dissection and aortic-dissection-related ischemia from its scope, focusing instead on occlusive acute mesenteric ischemia and emphasizing minimally invasive and multidisciplinary pathways [86]. Its existence highlights the deliberate separation between acute mesenteric ischemia of occlusive cause and the distinct pathology of spontaneous isolated visceral dissection that the SISMAD guideline targets [86,10].
8.7 Position of the Chinese Guideline
Against this landscape, the 2025 Chinese guideline is not a competitor but the first dedicated, formal evidence-graded guidance for SISMAD as a standalone entity. Its relative novelty is that SISMAD is carved out of the larger mesenteric-ischemia documents and given its own topic-by-topic recommendation set [10]. Its principal limitation — shared with every predecessor document — is the low quality of underlying evidence: no randomized trial exists anywhere for SISMAD (the registries surveyed in Section 9 are all observational), and the guideline’s honest level-C-heavy recommendation profile reflects this [10,83,34].
9. Trial Registries and the Research Pipeline
The ClinicalTrials.gov evidence landscape for SISMAD is thin but active, and it is summarized in Table 5. Three registrations are relevant:
- NCT05171842 — “Safety and Efficacy of Endovascular Treatment in Patients With Spontaneous Isolated Superior Mesenteric Artery Dissection: a Multicenter, Prospective Single-arm Observational Study.” Status: COMPLETED (enrollment 136; start 2021-09-09; completion 2025-02-28). Evaluates prognosis of patients treated with bare stents via femoral or brachial approach [88].
- NCT05342233 — “Comparison of Conservative and Endovascular Treatment for Spontaneously Isolated Superior Mesenteric Artery Dissection: A Real-world, Multicenter, Observational Study.” Status: RECRUITING (enrollment target 200; start 2022-04-30; completion projected 2028-04-01). Compares blood-pressure control/bowel rest/antithrombotics/nutritional support versus endovascular treatment [89].
- NCT03669380 — “Isolated Superior Mesenteric Artery Dissection With Concomitant Vascular Aberrancy.” Status: COMPLETED (enrollment 57; 2018). CT-morphology study of alarming features during conservative treatment [90].
All of these are observational; there is no registered randomized controlled trial comparing medical versus interventional management of SISMAD as of the preparation date. This is the decisive gap that the guideline’s call for “well-designed clinical studies and prospective research” points to [10]. The multicenter prospective cohort NCT05171842 (completed) and NCAT05342233 (recruiting, 200 patients) will provide the strongest prospective evidence to date, but both are non-randomized.
10. Discussion, Unresolved Questions, and Conclusions
10.1 Balanced Assessment
SISMAD has reframed itself over three decades from a near-uniformly fatal surgical emergency into a manageable, largely conservative-by-first-intention vascular condition. The 2025 ISMAD2022 guideline is a milestone: it is the first evidence-graded, dedicated clinical practice guideline for the entity, and its 19 recommendations across eight topics give clinicians, for the first time, an explicit scaffold for diagnosis, classification, medical therapy, intervention, and follow-up [10]. The strongest evidence behind it supports conservative-first management of uncomplicated disease, definition of high-risk imaging features (severe true-lumen stenosis, aneurysm, long dissection, patent false lumen), and the use of endovascular stenting (with or without coiling) for persistent symptoms, progression, or ischemic threat [11,12,20,60,34,15,14,75].
The main counterweights are three. First, evidence quality: virtually the entire pyramid below the guideline rests on retrospective cohorts and meta-analyses of cohorts; the guideline itself states that only a minority of its recommendations are supported by high-quality evidence [10]. Second, the antithrombotic question: multiple analyses and meta-analyses find no benefit and possible harm, yet antithrombotics remain widely prescribed, including in a third to half of administrative practice [13,11,6,4]. Third, the interventional-versus-medical outcome gap: stenting reliably improves anatomical remodeling and freedom from stenosis but has not been shown to improve mortality or long-term symptom recurrence in pooled data [15,69,14]. Any recommendation to treat aggressively must therefore be justified by anatomy (risk of ischemia/rupture) rather than by a general expectation of better outcomes.
10.2 Evidence-Quality Limitations (of This Review and of the Field)
The limitations section (Section 11) details the constraints of the underlying literature and of this synthesis. The most important field-level limitations are: (1) no randomized trials; (2) retrospective, single/multi-center case series with heterogeneous treatment protocols [11,12,34]; (3) inconsistent use of classification systems across studies [47,66]; (4) publication and reporting bias (Chinese-language literature, hospital-volume effects) [4,87]; (5) short follow-up in many series relative to late remodeling (which can occur over years) [25,20,14]; (6) limited reconciliation between imaging-based remodeling and patient-centered outcomes [15]; and (7) restricted access to the guideline’s full text, which places some recommendations beyond independent verification here [10].
10.3 Unresolved Questions
- What is the true incidence? Administrative data consistently find hundreds of cases per year in Japan while simultaneously showing high rates of incidental/asymptomatic diagnosis; the boundary between clinically significant and clinically trivial SISMAD is unresolved [5,6,34].
- Do antithrombotics help any subgroup? Might symptomatic patients with extensive intraluminal thrombus, distal emboli, or persistent pain benefit from a short course of anticoagulation? The pooled evidence says no for the average patient, but no subgroup analysis is adequate [13,11,34].
- Which classification should be standard? At least eight systems exist; the ISMAD2022 group showed Tan’s outperforms others for predicting conservative failure, but no system is externally validated or universally adopted [66,10,61].
- Is stenting worth it for remodeling alone? Given equivalent mortality/recurrence in meta-analytic comparisons, the value of higher remodeling after stenting — and the role of BMSAC versus bare stents — needs prospective, patient-important-outcome confirmation [15,75,71].
- What is the optimal surveillance protocol? The frequency and duration of CTA follow-up vary widely (3-month, 6-month, yearly); dose and cost trade-offs have not been studied [20,28,74].
- Do connective-tissue genotypes change management? The 34% pathogenic-variant yield and COL3A1’s strong association with endovascular need raise the question of routine genetic screening in young or atypical SISMAD patients [36].
- When is endovascular treatment appropriate, in a patient with >70% stenosis but well-controlled symptoms? The safety of primary conservative therapy even in severely compressed true lumens [59] suggests the traditional intervention triggers may be too aggressive.
10.4 Conclusions
SISMAD is a distinct, increasingly recognized vascular emergency whose modern management is dominated by conservative-first care guided by CTA-based classification. The 2025 Chinese guideline condenses 35 years of accumulated case-series evidence into 19 graded recommendations, establishing the first dedicated clinical practice blueprint and explicitly flagging its own evidence ceiling [10,1]. On the basis of this review, the credible clinical synthesis is: diagnose with CTA; classify; manage the majority conservatively with blood-pressure control and avoid routine antithrombotics; intervene endovascularly (stent ± coiling) for persistent symptoms, severe true-lumen stenosis, enlarging dissecting aneurysm, or progression; and operate without delay for bowel infarction, peritonitis, rupture, or failed endovascular treatment [17,20,13,34,10]. The decisive events of the next five years will be the results of the recruiting prospective cohort (NCT05342233), the completed single-arm stenting registry (NCT05171842), any movement toward a first randomized trial, and the external validation of predictive classifications [66,88,89]. Until then, the guideline’s most valuable—and most cited—sentiment stands: most of what we recommend rests on low-quality evidence, and the disease’s benign course in most patients should temper rather than license aggressive intervention [10,67].
11. Limitations
11.1 Limitations of This Review
- Full-text constraint on the guideline. The 2025 guideline (PMID 42335989) is published in Annals of Vascular Surgery behind a subscription paywall (Europe PMC lists it as “Subscription required”; not in PMC). This review verifies the guideline’s existence, authorship, methodology (GRADE + ESC grading), scope (eight topics), output (19 recommendations), and self-reported evidence-quality profile from its indexed abstract, and uses its companion publications for quantitative content [10,66,67]. Individual verbatim wording of the 19 recommendations could not be independently verified; Table 1 therefore summarizes scope rather than reproducing each recommendation verbatim. Readers with full-text access should reconcile the numbered recommendations directly.
- Classification definitions. Several classification systems (Yun, Li, Luan, Tan) are described qualitatively on the basis of how they are used in the cited studies; their complete subtype definitions sit in subscription/full-text material not exhaustively re-derived here. The Sakamoto scheme and the Qiu scheme (with computational validation) are described in the greatest detail because their source abstracts are the most explicit [17,52].
- Statistical measures. Every quantitative claim in this review is drawn from a verified abstract or official registry record. Where a figure appeared only in secondary or non-verifiable sources it was excluded or flagged. Pooled estimates are reported exactly as in the source meta-analyses, including their confidence intervals where stated.
- Language and geography bias. A large share of the SISMAD literature is Chinese- and Korean-language; the ISMAD2016 review found 622 patients in the Chinese-language literature alone [4]. This may inflate Asian representation and limit generalizability to Western populations.
- No STARD/PRISMA re-analysis. This is a narrative but heavily source-verified review, not a fresh systematic review; the pooled numbers reproduce the published meta-analyses without re-analysis of primary data.
- Cf. template structure. The review follows the xenon-template structure (abstract, numbered sections, tables, Vancouver references). Figures from the template are omitted because no figure-generation tool was available; tables substitute.
11.2 Limitations of the Underlying Evidence (Field Level)
- No randomized controlled trial has been conducted for SISMAD; the highest evidence class available is meta-analyses of observational case series [11,12,34].
- Heterogeneous and inconsistent treatment protocols across institutions and eras; several comparative studies are confounded by indication (sicker patients stented first) [11,15,14].
- Publication/reporting bias: favorable outcomes for stenting may be over-represented in single-arm device series [71].
- Follow-up duration is short in many series relative to the years-long remodeling process [25,20,14].
- The guideline’s own authors state that only a minority of recommendations are supported by high-quality evidence — the single most important limitation to carry into clinical application [10].
Tables
Table 1. Scope and Methods of the 2025 ISMAD2022 SISMAD Guideline
| Item | Detail | Source |
|---|---|---|
| Title | Clinical Practice Guideline for Spontaneous Isolated Superior Mesenteric Artery Dissection (2025 Edition) | [10] |
| Publisher/journal | Annals of Vascular Surgery; 2026;132:169–186 (Epub 23 Jun 2026) | [10] |
| Author group | Chinese Spontaneous Isolated Superior Mesenteric Artery Dissection Collaboration Group (ISMAD2022); coordinated at Xiangya Hospital, Central South University | [10] |
| Methodology | GRADE-informed; ESC grading system (classes/levels A high, B moderate, C low) | [10] |
| Scope | Eight topics including clinical presentation, imaging evaluation, classification, medical management strategies, follow-up | [10] |
| Output | 19 recommendations | [10] |
| Self-assessed evidence quality | Only a minority of recommendations supported by high-quality evidence; call for prospective studies | [10] |
| Companion quantitative work | Classification-comparison study (156 patients, 3 centers) in JACC Asia 2026 | [66] |
Table 2. Imaging Classification Systems for SISMAD
| System | Basis | Types | Predictive/clinical notes | Source |
|---|---|---|---|---|
| Sakamoto (2007) | False-lumen morphology on CTA | I patent FL (entry+re-entry); II cul-de-sac, no re-entry; III thrombosed FL with ULP; IV thrombosed FL without ULP | Type IV most conservatively responsive (82.1% in Huang series); types III/IV dominate acute presentations | [17,63,33] |
| Yun | CT configuration | Four types (I, IIa/IIb, …) per study-specific operational definitions | Type IIb common (63.6%); used in no-antithrombotic outcomes studies | [29,54,7] |
| Li | Morphology (I–V) | Five types | Described as more precise/complete; guides treatment; used in Riolan’s-arch and CFD studies | [61,64,65] |
| Luan | Morphology | Types (e.g., type B) | Best conservative outcomes for type B | [4] |
| Qiu | False-lumen structure (I–V) + patency (P/S) | Five types by FL structure; P=patent, S=stenotic true lumen | CFD-validated: significant differences in TAWSS/OSI/RRT across types | [52] |
| Tan | Imaging composite | (System-specific) | Best predictor of conservative-management failure: C-statistic 0.750 (95% CI 0.670–0.830) among 8 systems in ISMAD2022 study | [66] |
| HX (novel) | Flow type (CFD-based) | I dual-lumen flow (Ia/Ib); II single-lumen flow | Intervention if rupture/entrance-area ratio >0.44 (Type I) or min/max diameter <0.38 (Type II); not yet externally validated | [65] |
Table 3. Key Cohort and Registry Evidence (Conservative-First Outcomes)
| Study (year) | N | Setting | Key outcome | Source |
|---|---|---|---|---|
| Yun (2009) | 32 | Korea, single center | No CT progression; no benefit of anticoagulation/antiplatelet (P = 1.00) | [39] |
| Park (2011) | 46 (conservative of 58) | Korea, single center, median F/U 23 mo | FL smaller 41.3%, no change 43.5%, complete remodeling 15.2%; no progression; no SISMAD mortality | [25] |
| Min (2011) | 14 (symptomatic) | Korea, single center | Conservative 7, stenting 6, resection 1; fasting 2.5 vs 8.0 days | [23] |
| Heo (2017) | 116 | Korea, Samsung, 15 y | 96% pain resolution of 83 conservative symptomatic; 20% late recurrence; remodeling 63% partial/complete; 2% aneurysm | [20] |
| Tomita (2016) | 59 | Japan, Keio, ≥2 y F/U | Complete remodeling 64.0% of 25 conservative symptomatic; patent FL + aneurysm negative factors | [27] |
| Kimura (2017) | 35 | Japan, two centers | Complete remodeling 31%; favored by symptoms + no FL flow at diagnosis | [28] |
| Kim (2018) | 29 | Korea | Conservative without antithrombotics sufficient; no death | [29] |
| Naganuma (2016) | 715 ISMAD (admin) | Japan DPC, 18.3 M admissions | 14 total in-hospital deaths across all branch dissections; most treated conservatively | [5] |
| Mizuno (2018) | 221 ISMAD | Japan, 141 hospitals | 1 in-hospital death (0.5%); surgery 5.4%; antithrombotic use 1/3 | [6] |
| Lei (2022) | 110 | China, Wenzhou registry | 32 misdiagnosed/missed; 3.6% bowel necrosis; 63.6% Yun IIb | [7] |
| Hau (2023) | 78 (cell+ SMA) | Hong Kong | 5-y survival 96%, 10-y 91%; only 3 interventions | [9] |
Table 4. Meta-Analyses and Systematic Reviews (Management)
| Review (year) | Studies/N | Key pooled findings | Source |
|---|---|---|---|
| Zhu (2018) | 25 studies/616 cases | Conservative initial 87.0%; success 84.7%; conversion 14.3%; no antithrombotic benefit (17.8% vs 10.1% failure, P=0.103) | [11] |
| Wang (2018) | 43 studies | Symptomatic conservative → late secondary intervention: SICAD 8%, SISMAD 12%; asymptomatic 0%. Complete remodeling SICAD 64% vs SISMAD 25%; mortality 0–1% | [40] |
| Karaolanis (2019) | 30 studies/729 | Conservative resolution 92.8%; conversions to endovascular 12.3%, open 4.4%; bowel ischemia 3.75%; complete remodeling 32% (conservative) | [12] |
| Ahn (2019) | 35 articles/727 | Antithrombotics no benefit (RR 0.96–0.97); not recommended | [13] |
| Acosta (2021) | 97 studies | Male/HTN/smoking risk; peritonitis 2.1% (SMA) vs 0%; splenic infarction 11.2% (celiac); ruptured pseudoaneurysm 0.4%; complete remodeling 43% | [34] |
| Shi (2023) | 80 reports/1040 | ISMAD prevalence 60%, ICAD 37%; male 80%; smoking/HTN leading risks | [8] |
| Zhang (2024a) | 9 comparative/672 | EST vs medical: no differences in early relief, reintervention, mortality; EST higher complete remodeling (OR 4.53), lower aneurysm (OR 0.19), longer stay | [15] |
| Wang (2024) | 21 studies/611 EST | Technique success ~94%, symptom resolution ~99%, complications ~1%, mortality <1%, stent stenosis 12%, patency 98%, complete remodeling 88% | [71] |
Table 5. Registry Landscape (ClinicalTrials.gov, verified via v2 API)
| NCT | Design | N | Status | Key features | Source |
|---|---|---|---|---|---|
| NCT05171842 | Multicenter, prospective, single-arm observational (stenting) | 136 | COMPLETED (2021–2025) | Bare-stent endovascular prognosis; femoral/brachial access | [88] |
| NCT05342233 | Real-world, multicenter, observational (conservative vs endovascular) | 200 | RECRUITING (2022–2028) | BP control, bowel rest, antithrombotics, nutrition vs endovascular | [89] |
| NCT03669380 | Retrospective CT-morphology study | 57 | COMPLETED (2018) | Alarming CT features during conservative treatment; vascular aberrancy | [90] |
Table 6. SISMAD Guideline Within the Guideline Landscape
| Document (year) | Sponsor | Scope | Relevance to SISMAD | Source |
|---|---|---|---|---|
| ESVS Mesenteric Guidelines (2017) | ESVS | Mesenteric arterial/venous disease incl. visceral dissection | Conservative-first; CTA diagnosis; endovascular rescue | [82] |
| WSES AMI Guidelines (2017) | WSES | Acute mesenteric ischemia (all causes) | Emergency CTA; damage control; 50% mortality context | [16] |
| ESC/ESVS PAD Guidelines (2017) | ESC/ESVS | Peripheral arterial disease incl. mesenteric | Grading framework (class/level) used by ISMAD2022 | [84] |
| SVS CMI Guidelines (2020) | SVS | Chronic mesenteric ischemia (atherosclerotic) | Background for chronic disease; endovascular-first with surveillance | [85] |
| ESVS Mesenteric & Renal Guidelines (2025) | ESVS | 102 recommendations incl. spontaneous isolated visceral artery dissection | Current European benchmark for visceral dissection | [83] |
| 2026 Beijing Consensus (AMI) | Beijing Med Assn + partners | Acute mesenteric arterial ischemia (explicitly excludes ISMAD & aortic-related) | Delineates boundary of ISMAD-specific guidance | [86] |
| ISMAD2022 SISMAD Guideline (2025) | Chinese ISMAD2022 Collaboration Group | SISMAD standalone | First dedicated evidence-graded SISMAD guideline; 19 recommendations | [10] |
References (Vancouver — PMID-verified 2026-09-21)
- Corbetti F; Vigo M; Bulzacchi A; Angelini F; Burigo E; Thiene G. CT diagnosis of spontaneous dissection of the superior mesenteric artery. J Comput Assist Tomogr. 1989;13(6):965-7. PMID 2685067.
- Vignati PV; Welch JP; Ellison L; Cohen JL. Acute mesenteric ischemia caused by isolated superior mesenteric artery dissection. J Vasc Surg. 1992;16(1):109-12. PMID 1619710.
- Sparks SR; Vasquez JC; Bergan JJ; Owens EL. Failure of nonoperative management of isolated superior mesenteric artery dissection. Ann Vasc Surg. 2000;14(2):105-9. PMID 10742422.
- Luan JY; Guan X; Li X; Wang CM; Li TR; Zhang L. Isolated superior mesenteric artery dissection in China. J Vasc Surg. 2016;63(2):530-6. PMID 26597665.
- Naganuma M; Matsui H; Fushimi K; Yasunaga H. Clinical features of isolated dissections of abdominal aortic branches. Heart Vessels. 2016;31(6):1006-9. PMID 25421008.
- Mizuno A; Iguchi H; Sawada Y; Nomura H; Komiyama N; Watanabe S. Real clinical management of patients with isolated superior mesenteric artery dissection in Japan. J Cardiol. 2018;71(2):155-158. PMID 28969970.
- Lei Y; Liu J; Lin Y; Li H; Song W; Li Z. Clinical characteristics and misdiagnosis of spontaneous isolated superior mesenteric artery dissection. BMC Cardiovasc Disord. 2022;22(1):239. PMID 35610570.
- Shi Y; Guo J; Dong J; Chen X; Luo L; Shen Y. Comparative analysis of prevalence, evaluation, management, and rehabilitation outcome of spontaneous isolated visceral artery dissection: a systematic review and meta-analysis of 80 reports. Int J Surg. 2023;109(3):469-480. PMID 36912770.
- Hau SF; Chan YC; Cheung GC; Cheng SW. Risk factor analysis and treatment outcome of patients with spontaneous isolated celiac axis or superior mesenteric artery dissection. J Vasc Surg. 2023;77(1):150-157. PMID 36087832.
- Ling J; Sun J; Hou Y; Wu M; Yuan P; Hou L. Clinical Practice Guideline for Spontaneous Isolated Superior Mesenteric Artery Dissection (2025 Edition). Ann Vasc Surg. 2026;132:169-186. PMID 42335989.
- Zhu Y; Peng Y; Xu M; Wei Y; Wu S; Guo W. Treatment Strategies and Outcomes of Symptomatic Spontaneous Isolated Superior Mesenteric Artery Dissection: A Systematic Review and Meta-analysis. J Endovasc Ther. 2018;25(5):640-648. PMID 30153774.
- Karaolanis G; Antonopoulos C; Tsilimigras DI; Moris D; Moulakakis K. Spontaneous isolated superior mesenteric artery dissection: Systematic review and meta-analysis. Vascular. 2019;27(3):324-337. PMID 30621507.
- Ahn S; Mo H; Han A; Min SI; Min SK; Ha J. The Use of Antithrombotics Is Not Beneficial for Conservative Management of Spontaneous Isolated Dissection of the Superior Mesenteric Artery: A Meta-analysis. Ann Vasc Surg. 2019;60:415-423.e4. PMID 31075482.
- Wang B; Pan J; Xu Y; Qiu X; Ding Z; Li D. Long-term Outcomes of Endovascular Versus Medical Treatment for Isolated Superior Mesenteric Artery Dissection: A 10-Year Retrospective Study. Cardiovasc Intervent Radiol. 2025;48(5):593-602. PMID 40011282.
- Zhang B; Shen Y; Jin L; Wang J. Systematic review and meta-analysis of current evidences in endograft therapy vs. medical treatment for Spontaneous Isolated Superior Mesenteric Artery Dissection. Langenbecks Arch Surg. 2024;409(1):215. PMID 39008150.
- Bala M; Kashuk J; Moore EE; Kluger Y; Biffl W; Gomes CA. Acute mesenteric ischemia: guidelines of the World Society of Emergency Surgery. World J Emerg Surg. 2017;12:38. PMID 28794797.
- Sakamoto I; Ogawa Y; Sueyoshi E; Fukui K; Murakami T; Uetani M. Imaging appearances and management of isolated spontaneous dissection of the superior mesenteric artery. Eur J Radiol. 2007;64(1):103-10. PMID 17628380.
- Kim YW. Current Understandings of Spontaneous Isolated Superior Mesenteric Artery Dissection. Vasc Specialist Int. 2016;32(2):37-43. PMID 27386450.
- Yasuhara H; Shigematsu H; Muto T. Self-limited spontaneous dissection of the main trunk of the superior mesenteric artery. J Vasc Surg. 1998;27(4):776-9. PMID 9576098.
- Heo SH; Kim YW; Woo SY; Park YJ; Park KB; Kim DK. Treatment strategy based on the natural course for patients with spontaneous isolated superior mesenteric artery dissection. J Vasc Surg. 2017;65(4):1142-1151. PMID 28216343.
- Leung DA; Schneider E; Kubik-Huch R; Marincek B; Pfammatter T. Acute mesenteric ischemia caused by spontaneous isolated dissection of the superior mesenteric artery: treatment by percutaneous stent placement. Eur Radiol. 2000;10(12):1916-9. PMID 11305570.
- Suzuki S; Furui S; Kohtake H; Sakamoto T; Yamasaki M; Furukawa A. Isolated dissection of the superior mesenteric artery: CT findings in six cases. Abdom Imaging. 2004;29(2):153-7. PMID 15290937.
- Min SI; Yoon KC; Min SK; Ahn SH; Jae HJ; Chung JW. Current strategy for the treatment of symptomatic spontaneous isolated dissection of superior mesenteric artery. J Vasc Surg. 2011;54(2):461-6. PMID 21571493.
- Cho BS; Lee MS; Lee MK; Choi YJ; Kim CN; Kang YJ. Treatment guidelines for isolated dissection of the superior mesenteric artery based on follow-up CT findings. Eur J Vasc Endovasc Surg. 2011;41(6):780-5. PMID 21333559.
- Park YJ; Park KB; Kim DI; Do YS; Kim DK; Kim YW. Natural history of spontaneous isolated superior mesenteric artery dissection derived from follow-up after conservative treatment. J Vasc Surg. 2011;54(6):1727-33. PMID 21944909.
- Luan JY; Li X; Li TR; Zhai GJ; Han JT. Vasodilator and endovascular therapy for isolated superior mesenteric artery dissection. J Vasc Surg. 2013;57(6):1612-20. PMID 23538008.
- Tomita K; Obara H; Sekimoto Y; Matsubara K; Watada S; Fujimura N. Evolution of Computed Tomographic Characteristics of Spontaneous Isolated Superior Mesenteric Artery Dissection During Conservative Management. Circ J. 2016;80(6):1452-9. PMID 27118619.
- Kimura Y; Kato T; Nagao K; Izumi T; Haruna T; Ueyama K. Outcomes and Radiographic Findings of Isolated Spontaneous Superior Mesenteric Artery Dissection. Eur J Vasc Endovasc Surg. 2017;53(2):276-281. PMID 28012909.
- Kim H; Park H; Park SJ; Park BW; Hwang JC; Seo YW. Outcomes of Spontaneous Isolated Superior Mesenteric Artery Dissection Without Antithrombotic Use. Eur J Vasc Endovasc Surg. 2018;55(1):132-137. PMID 29229279.
- Park YJ; Park CW; Park KB; Roh YN; Kim DI; Kim YW. Inference from clinical and fluid dynamic studies about underlying cause of spontaneous isolated superior mesenteric artery dissection. J Vasc Surg. 2011;53(1):80-6. PMID 20855179.
- Weng Y; Sun J; Lang D. Early and Mid-Term Outcomes of Endovascular Treatment for Symptomatic Spontaneous Isolated Superior Mesenteric Artery Dissection: A Retrospective Single-Center Study. Angiology. 2026. PMID 42124405.
- Ye M; Zhou Q; Wu J; Zhang Z; Li B; Zheng T. Conservative Versus Endovascular Treatment for Spontaneous Isolated Superior Mesenteric Artery Dissection: A Clinical and Imaging Follow-up Study. J Endovasc Ther. 2024;31(5):840-852. PMID 37026460.
- Huang T; Ye M; Wang J; Zheng T; Zhou Q. Role of Imaging Classification in Guiding Treatment Strategies for Spontaneous Isolated Superior Mesenteric Artery Dissection: A Comparative Study of Conservative and Endovascular Approaches. J Endovasc Ther. 2025. PMID 41452069.
- Acosta S; Gonçalves FB. Management of Spontaneous Isolated Mesenteric Artery Dissection: A Systematic Review. Scand J Surg. 2021;110(2):130-138. PMID 33724090.
- Skeik N; Smith J; Olson SL; Lohese OL; Mirza A; Manunga J. Mesenteric Artery Dissection and Wall-Thickening, Case Study and General Review. Angiology. 2023;74(1):7-21. PMID 35921630.
- Xie X; Jiao R; Chen F; Zhou W. Genetic Evaluation in Symptomatic Spontaneous Isolated Superior Mesenteric Artery Dissection. Angiology. 2026. PMID 41805381.
- Chen ZL; Zhang XC; Pan GR; Sun Y; Xu M; Li XQ. Clinical Features and Therapeutic Options for Isolated Visceral Artery Dissection. Ann Vasc Surg. 2016;30:227-35. PMID 26541969.
- Nakamura T; Osaka M; Mastuyama T; Harada S; Nakao T; Nobori S. Isolated Superior Mesenteric Artery Dissection Following Liver Transplant: Report of 3 Cases. Transplant Proc. 2019;51(5):1502-1505. PMID 31155183.
- Yun WS; Kim YW; Park KB; Cho SK; Do YS; Lee KB. Clinical and angiographic follow-up of spontaneous isolated superior mesenteric artery dissection. Eur J Vasc Endovasc Surg. 2009;37(5):572-7. PMID 19208448.
- Wang J; He Y; Zhao J; Yuan D; Xu H; Ma Y. Systematic review and meta-analysis of current evidence in spontaneous isolated celiac and superior mesenteric artery dissection. J Vasc Surg. 2018;68(4):1228-1240.e9. PMID 30126785.
- Wu Z; Yi J; Xu H; Guo W; Wang L; Chen D. The Significance of the Angle between Superior Mesenteric Artery and Aorta in Spontaneous Isolated Superior Mesenteric Artery Dissection. Ann Vasc Surg. 2017;45:117-126. PMID 28689953.
- Kim H; Labropoulos N. The role of aortomesenteric angle in occurrence of spontaneous isolated superior mesenteric artery dissection. Int Angiol. 2020;39(2):125-130. PMID 32052950.
- Shi Y; Zhou Y; Yuan Y; Chen L; He X; Su H. Association between aortomesenteric angle and symptomatic spontaneous isolated superior mesenteric artery dissection. Sci Rep. 2025;15(1):8605. PMID 40074763.
- Jia Z; Mei J; Ding W; Zhao X; Gong W; Yu H. The pathogenesis of superior mesenteric artery dissection: An in-depth study based on fluid-structure interaction and histology analysis. Comput Methods Programs Biomed. 2022;226:107187. PMID 36279640.
- Mei J; Ding W; Yu H; Zhao X; Xu H; Wang K. Different hemodynamic factors cause the occurrence of superior mesenteric atherosclerotic stenosis and superior mesenteric artery dissection. Front Cardiovasc Med. 2023;10:1121224. PMID 37144058.
- Hou L; Yin K; Xiong J; Weng C; Wang J; Qi Y. The morphological pathogenesis of isolated superior mesenteric artery dissection. Front Cardiovasc Med. 2025;12:1653988. PMID 41143194.
- Dou L; Tang H; Zheng P; Wang C; Li D; Yang J. Isolated superior mesenteric artery dissection: CTA features and clinical relevance. Abdom Radiol (NY). 2020;45(9):2879-2885. PMID 31401677.
- Ben Abdallah I; Craiem D; Casciaro M; Deza D; Ronot M; Corcos O. Case-Control Study of 3D Morphology in Isolated Mesenteric Artery Dissection. Cardiovasc Eng Technol. 2023;14(2):230-238. PMID 36471224.
- Ben Abdallah I; Craiem D; Casciaro M; Deza D; Garzelli L; Nuzzo A. Volumetric Analysis of Progressive Remodeling of Isolated Mesenteric Artery Dissection Treated by Conservative Therapy. J Vasc Interv Radiol. 2023;34(3):445-453. PMID 36400121.
- Wei R; Chen Z. Hemodynamic characterization of spontaneous isolated superior mesenteric artery dissection revealed by patient-specific computational fluid dynamics. Biomed Eng Online. 2025;24(1):101. PMID 40817066.
- Mei J; Yuan Y; Yan H; Zhao X; Xue T; Su H. Factors associated with false lumen changes in patients with superior mesenteric artery dissection. Vasc Med. 2024;29(3):274-285. PMID 38334057.
- Zhang X; Chen J; Qiu C; He Y; Wang B; Zhang H. Validation of classification system for isolated superior mesenteric artery dissections using image-based computational flow analysis. Comput Methods Programs Biomed. 2024;255:108364. PMID 39146760.
- Ginsburg M, Obara P, Lambert DL, Hanley M, Steigner ML, Camacho MA, et al. ACR Appropriateness Criteria(®) Imaging of Mesenteric Ischemia. J Am Coll Radiol. 2018;15(11S):S332-S340. PMID 30392602.
- Tan Z; Jin Q; Fan W; Han P; Li X. Clinical implications of perivascular fat stranding surrounding spontaneous isolated superior mesenteric artery dissection on computed tomography. Exp Ther Med. 2021;21(1):34. PMID 33262820.
- Lei YL; Song WX; Lin Y; Li HP; Lyu HP; Chen JZ. The ratio of superior mesenteric artery diameter to superior mesenteric vein diameter based on non-enhanced computed tomography in the early diagnosis of spontaneous isolated superior mesenteric artery dissection. World J Emerg Med. 2022;13(3):202-207. PMID 35646218.
- Kato J; Sugihara T; Koda M; Tokunaga S; Nagahara T; Matono T. Ultrasonographic findings in isolated superior mesenteric artery dissection. J Med Ultrason (2001). 2010;37(3):147-8. PMID 27278015.
- Hashidomi H; Saito S. Spontaneous isolated superior mesenteric artery dissection treated under intravascular ultrasound guidance. Cardiovasc Interv Ther. 2011;26(3):269-73. PMID 24122595.
- He Q; Yu F; Fu Y; Yang B; Huo R; Xian R. Evaluation of isolated abdominal visceral artery dissection with multi-scale spiral computed tomography: a retrospective case series. J Cardiothorac Surg. 2021;16(1):61. PMID 33781323.
- Chen W; Shi H; Wang K; Li S; Tian F; Jia Z. Primary Conservative Therapy for Symptomatic Isolated Mesenteric Artery Dissection with Severely Compressed True Lumen or Large Dissecting Aneurysm. J Vasc Interv Radiol. 2021;32(1):49-55. PMID 33248917.
- Shi Y; Ni G; Zhao B; Gu J; Huang H; Lu Z. Management of Symptomatic Spontaneous Isolated Superior Mesenteric Artery Dissection: A Single Centre Experience with Mid Term Follow Up. Eur J Vasc Endovasc Surg. 2020;60(6):863-871. PMID 33032925.
- Jia Z; Tu J; Jiang G. The Classification and Management Strategy of Spontaneous Isolated Superior Mesenteric Artery Dissection. Korean Circ J. 2017;47(4):425-431. PMID 28765730.
- DeCarlo C; Ganguli S; Borges JC; Schainfeld RM; Mintz AJ; Mintz J. Presentation, treatment, and outcomes in patients with spontaneous isolated celiac and superior mesenteric artery dissection. Vasc Med. 2017;22(6):505-511. PMID 28901215.
- Yoshida R; Yoshizako T; Maruyama M; Takinami Y; Shimojo Y; Tamaki Y. The value of CT findings for prognostic prediction of spontaneous superior mesenteric artery dissection. Acta Radiol. 2019;60(4):542-548. PMID 29950110.
- Peng Y; Li R; Tang G; Wang K; Sun M; Guan J. Correlation of Riolan’s arch diameter to treatment choice in patients with isolated superior mesenteric artery dissection. Abdom Radiol (NY). 2022;47(10):3628-3637. PMID 35913506.
- Xu H; Yin K; Weng C; Yuan D; Zheng T. Morphology and computational fluid dynamics support a novel classification of Spontaneous isolated superior mesenteric artery dissection. J Biomech. 2025;182:112587. PMID 39970629.
- Ling J; Hou L; Wu M; Chen Y; Yuan D; Xiong J. Predictive Value of Imaging-Based Classifications for Conservative Management Failure in Isolated Superior Mesenteric Artery Dissection. JACC Asia. 2026;6(8 Pt 1):1500-1512. PMID 42313014.
- He M; Liu Z. Beyond Classification: Rethinking Risk Stratification in Isolated Superior Mesenteric Artery Dissection. JACC Asia. 2026;6(8 Pt 1):1513-1516. PMID 42554394.
- Alcantara S; Yang CK; Sasson J; Goss S; Benvenisty A; Todd G. The evidence for nonoperative management of visceral artery dissections: a single-center experience. Ann Vasc Surg. 2015;29(1):103-8. PMID 25277054.
- Gao P; Li G; Chen J; Qiu R; Qiao C; Luo K. The impact of endovascular treatment on clinical outcomes of stable symptomatic patients with spontaneous superior mesenteric artery dissection. J Vasc Surg. 2021;73(4):1269-1276. PMID 32956796.
- Xu Y; Li X; Shang D; Liu J; Jin B; Chen W. Mid-term outcomes of symptomatic isolated superior mesenteric artery dissection with endovascular management. Vascular. 2021;29(2):301-310. PMID 32819204.
- Wang J; Luan F; Bai Z; Liu Z. Systematic review and meta-analysis of current evidence in endograft therapy for spontaneous isolated superior mesenteric artery dissection. Updates Surg. 2024;76(4):1169-1181. PMID 38546969.
- Xu L; Shao J; Zhang D; Qiu C; Wang J; Li K. Long-term outcomes of conservative treatment and endovascular treatment in patients with symptomatic spontaneous isolated superior mesenteric artery dissection: a single-center experience. BMC Cardiovasc Disord. 2020;20(1):256. PMID 32471346.
- Ji J; Xie Y; Bai Z; Deng G; Zhao G; Qin Y. Placement of Bare Self-Expanding Metal Stent for Isolated Superior Mesenteric Artery Dissection. Ann Vasc Surg. 2023;96:223-231. PMID 37230317.
- Mei J; Yan H; Zhao X; Yuan Y; Su H; Xue T. In-stent Restenosis After Stenting for Superior Mesenteric Artery Dissection Is Associated With Stent Landing Zone: From Clinical Prediction to Hemodynamic Mechanisms. J Endovasc Ther. 2025;32(6):2169-2182. PMID 38561992.
- Qi X; Tang B; Zhang H; Fu J; Chen Y; Luo H. Midterm Results of the Conservative, Bare Stent, and Bare Stent-Assisted Coiling Treatments for Symptomatic Isolated Superior Mesenteric Artery Dissection. Ann Vasc Surg. 2023;96:232-240. PMID 37169250.
- Yamaguchi H; Murata S; Ueda T; Mine T; Onozawa S; Hayashi H. New technique for false lumen coiling of spontaneous isolated superior mesenteric artery dissection. CVIR Endovasc. 2021;4(1):35. PMID 33826016.
- Gouëffic Y; Costargent A; Dupas B; Heymann MF; Chaillou P; Patra P. Superior mesenteric artery dissection: case report. J Vasc Surg. 2002;35(5):1003-5. PMID 12021719.
- Picquet J; Abilez O; Pénard J; Jousset Y; Rousselet MC; Enon B. Superficial femoral artery transposition repair for isolated superior mesenteric artery dissection. J Vasc Surg. 2005;42(4):788-91. PMID 16242570.
- Cirillo-Penn NC; DeMartino RR; Rasmussen TE; Shuja F; Colglazier JJ; Kalra M. Midterm Clinical Outcomes of Retrograde Open Mesenteric Stenting for Mesenteric Ischemia. Ann Vasc Surg. 2023;89:20-27. PMID 36404451.
- Jeong MJ; Kwon H; Kim A; Ko GY; Han Y; Kwon TW. Clinical Outcomes of Conservative Treatment in Patients with Symptomatic Isolated Spontaneous Renal Artery Dissection and Comparison with Superior Mesenteric Artery Dissection. Eur J Vasc Endovasc Surg. 2018;56(2):291-297. PMID 29859822.
- Wang L; Xu M; Chen Z; Jiang G. Conservative versus stent treatment for spontaneous isolated superior mesenteric artery dissection after the failure of initial 3 days’ conservative treatment: A 10-year follow-up study. Vascular. 2025;33(1):96-101. PMID 38427949.
- Björck M; Koelemay M; Acosta S; Bastos Goncalves F; Kölbel T; Kolkman JJ. Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2017;53(4):460-510. PMID 28359440.
- Koelemay MJ; Geelkerken RH; Kärkkäinen J; Leone N; Antoniou GA; de Bruin JL. European Society for Vascular Surgery (ESVS) 2025 Clinical Practice Guidelines on the Management of Diseases of the Mesenteric and Renal Arteries and Veins. Eur J Vasc Endovasc Surg. 2025;70(2):153-218. PMID 40513642.
- Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J. 2018;39(9):763-816. PMID 28886620.
- Huber TS; Björck M; Chandra A; Clouse WD; Dalsing MC; Oderich GS. Chronic mesenteric ischemia: Clinical practice guidelines from the Society for Vascular Surgery. J Vasc Surg. 2021;73(1S):87S-115S. PMID 33171195.
- Splanchnic Vascular Group of Vascular Surgery Branch, Beijing Medical Association, Vascular Surgery Branch; China International Exchange and Promotive Association for Medical and Health Care; Bowel Stroke Multidisciplinary Working Group of Beijing Tsinghua Changgung Hospital. [Multidisciplinary expert consensus on acute mesenteric arterial ischemia (2026 edition)]. Zhonghua Wai Ke Za Zhi. 2026;64(2):104-110. PMID 41667922.
- Hou L; Wang T; Wang J; Yuan D. Isolated superior mesenteric artery dissection in China: A systematic review and meta-analysis. Asian J Surg. 2022;45(4):1070-1074. PMID 35183417.
- NCT05171842. Safety and Efficacy of Endovascular Treatment in Patients With Spontaneous Isolated Superior Mesenteric Artery Dissection: a Multicenter, Prospective Single-arm Observational Study. ClinicalTrials.gov. Status: Completed (started 2021-09-09; completion 2025-02-28). https://clinicaltrials.gov/study/NCT05171842
- NCT05342233. Comparison of Conservative and Endovascular Treatment for Spontaneously Isolated Superior Mesenteric Artery Dissection: A Real-world, Multicenter, Observational Study. ClinicalTrials.gov. Status: Recruiting (started 2022-04-30; estimated completion 2028-04-01). https://clinicaltrials.gov/study/NCT05342233
- NCT03669380. Isolated Superior Mesenteric Artery Dissection With Concomitant Vascular Aberrancy: Extremely Rare Cases and Clinical Implications. ClinicalTrials.gov. Status: Completed (2018). https://clinicaltrials.gov/study/NCT03669380
Review complete as of the preparation date. PMID verification via NCBI E-utilities esummary (all references verified on 2026-09-21); registry data via ClinicalTrials.gov v2 API. Research-agent briefs, PMID verification logs, and source materials are preserved in the project directory; provenance sidecar accompanies this file.